1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH Small Business Innovation Research (SBIR) Phase I (R43/U43) Clinical Trial Optional is sponsored by National Institutes of Health (NIH). The NIH SBIR program provides non-dilutive funding to small businesses for early-stage research and development with strong potential for commercialization in biomedical and behavioral science. This includes projects that aim to improve health and save lives.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: United States-based small business concerns (SBCs). Small businesses must meet SBA size standards for most industries. Confirm the full requirements in the official notice before applying.
The current listing shows up to $323,090 for Phase I (CDC SBIR). Up to $1.4 billion annually across NIH for small business programs. Verify award ceilings, matching requirements, and allowable costs in the official notice.
NIH Small Business Innovation Research (SBIR) Phase I (R43/U43) Clinical Trial Optional is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article